Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation

Brian A. Aguado 1,2, Katherine B. Schuetze 3,4, Joseph C. Grim 1,2, Cierra J. Walker 2,5, Anne C. Cox 1, Tova L. Ceccato 2,6, Aik-Choon Tan 7, Carmen C. Sucharov 3, Leslie A. Leinwand 2,6, Matthew R. G. Taylor 8, Timothy A. McKinsey 3,4*, Kristi S. Anseth 1,2*

The transcatheter aortic valve replacement (TAVR) procedure has emerged as a minimally invasive treatment for patients with aortic valve stenosis (AVS). However, alterations in serum factor composition and biological activity after TAVR remain unknown. Here, we quantified the systemic inflammatory effects of the TAVR procedure and hypothesized that alterations in serum factor composition would modulate valve and cardiac fibrosis. Serum samples were obtained from patients with AVS immediately before their TAVR procedure (pre-TAVR) and about 1 month afterward (post-TAVR). Aptamer-based proteomic profiling revealed alterations in post-TAVR serum composition, and ontological analysis identified inflammatory macrophage factors implicated in myofibroblast activation and deactivation. Hydrogel biomaterials used as valve matrix mimics demonstrated that post-TAVR serum reduced myofibroblast activation of valvular interstitial cells relative to pre-TAVR serum from the same patient. Transcriptomics and curated network analysis revealed a shift in myofibroblast phenotype from pre-TAVR to post-TAVR and identified p38 MAPK signaling as one pathway involved in pre-TAVR–mediated myofibroblast activation. Post-TAVR serum deactivated valve and cardiac myofibroblasts initially exposed to pre-TAVR serum to a quiescent fibroblast phenotype. Our in vitro deactivation data correlated with patient disease severity measured via echocardiography and multimorbidity scores, and correlations were dependent on hydrogel stiffness. Sex differences in cellular responses to male and female sera were also observed and may corroborate clinical observations regarding sex-specific TAVR outcomes. Together, alterations in serum composition after TAVR may lead to an antifibrotic fibroblast phenotype, which suggests earlier interventions may be beneficial for patients with advanced AVS to prevent further disease progression.

INTRODUCTION
Severe aortic valve stenosis (AVS) is a progressive disease characterized by aberrant fibrosis and/or calcification of aortic valve leaflets, leading to inadequate blood flow (1). AVS affects more than the aortic valve; patients also experience increased cardiac hypertrophy and fibrosis during disease progression, which eventually leads to heart failure (2–4). The prevalence of degenerative AVS increases with patient age, affecting 12.4% of the population over 75 years old, and is considered severe in 3.4% of patients (3). Unfortunately, over 50% of patients succumb to severe AVS 2 years after diagnosis if the disease remains untreated (5). Currently, surgical or transcatheter aortic valve replacements (SAVR or TAVR) serve as the gold standard of treatment for AVS, where a biomaterial-based artificial valve is implanted at the aortic valve site to restore efficient blood flow (6–8). The transfemoral and transapical TAVR procedures were approved for patient use by the Food and Drug Administration in 2011 and 2012, respectively, as less-invasive alternatives to SAVR for high-risk and/or elderly patients (9). Randomized clinical trials suggest that patients receiving TAVR show comparable survival rate outcomes to patients receiving SAVR and that TAVR reverses left ventricular hypertrophy and fibrosis in high-risk surgical patients (9, 10). Hence, there is a need to improve our understanding of how fibrotic tissue remodels after a TAVR procedure and how patient-specific responses to a valve implant may dictate TAVR outcomes.

One hallmark and key mediator of AVS progression is the chronic activation of tissue-specific fibroblasts to myofibroblasts, which are known to cause aberrant tissue stiffening and subsequent fibrosis upon repeated tissue injury (11). Valvular interstitial cells (VICS) activate to myofibroblasts to maintain tissue homeostasis during routine valve injury but remain persistently activated during AVS progression, accompanied by pathological stiffening of the valve leaflets (11). Likewise, patients with AVS experience increased hemodynamic and mechanical stresses during disease progression, subsequently driving increased myofibroblast activation in cardiac tissues (12). After a TAVR procedure, hemodynamic and mechanical stresses on the valve and cardiac tissues are substantially reduced, which can improve left ventricle (LV) function and reduce myofibroblast activation and/or promote myofibroblast deactivation in subsets of patients with AVS (13). Although reductions in mechanical stress likely account for partial reductions or reversal in myofibroblast activity, additional biological mechanisms may also be involved in regulating observed reductions in myofibroblast activation after a TAVR procedure.

Here, serum from patients with AVS was collected before and after a TAVR procedure to elucidate changes in key biological signals that
may regulate myofibroblast phenotype after surgery. Postprocedural inflammation has been hypothesized to play a role in mediating TAVR patient outcomes (14). We posit that the systemic inflammatory response to the valve implant and subsequent release of inflammatory cytokines in patient serum may influence fibrotic valve tissue remodeling via regulation of myofibroblasts. We hypothesized that the combination of inflammatory factors in patient serum before TAVR would activate VICs and cardiac fibroblasts to a myofibroblast state, whereas serum factors after TAVR would participate in reversing myofibroblast activation. To test this hypothesis, we characterized the proteome of patient serum samples before and after a TAVR procedure to quantify the global alterations in serum composition and ontologically identified candidate inflammatory factors that may mediate myofibroblast activation (bone morphogenic protein 6 (BMP-6), chemokine C-X-C motif 9 (CXCL9), and interferon-γ (IFN-γ)) and de-activation [tumor necrosis factor–α (TNF-α) and interleukin-1β (IL-1β)].

We used patient sera to treat VICs and adult rat ventricular fibroblasts (ARVs) cultured on hydrogels that mimic the valve and cardiac extracellular matrix (ECM) to assess myofibroblast activation as a function of serum factors. Quantifying the dynamic alterations in the composition of inflammatory cytokines after a TAVR procedure may provide insight into the role of circulating serum factors on the fibroblast-to-myofibroblast transition and potential signals that reverse the pathogenic myofibroblast phenotype in patients with AVS.

RESULTS

Pre-TAVR serum activates fibroblasts, whereas post-TAVR serum maintains quiescence

We hypothesized that circulating serum factors in patients with AVS would be altered in response to a TAVR procedure due to the inflammatory response to the implant, which would subsequently affect myofibroblast phenotypes (15). Serum samples were collected from patients immediately before and about 1 month after their TAVR procedure (table S1 in data file S1). Proteomic characterization of patient sera was performed using a SOMAscan DNA aptamer array, where the relative abundances of 1317 proteins were quantified. After comparing the log₂-transformed relative fluorescence unit (RFU) values representing protein abundance before and after the TAVR procedure, we identified 283 differentially regulated proteins [false discovery rate (FDR)–adjusted P < 0.05; table S2 in data file S1]. A total of 156 proteins were more abundant in pre-TAVR serum, and 127 proteins were more abundant in post-TAVR serum. Unsupervised hierarchical clustering of differentially expressed serum proteins, based on correlation distance and average linkage, revealed clustering of protein composition for 8 of 12 pre-TAVR and 8 of 12 post-TAVR serum samples (Fig. 1A). SOMAscan data were subsequently analyzed using a scaled principal component analysis (PCA) to visualize variation between serum samples before and after a TAVR procedure. Principal component (PC) 1 (45.3%) differentiated pre-TAVR and post-TAVR samples into clustered groups, suggesting a shift in serum protein composition after a TAVR procedure (Fig. 1B).

Next, we queried whether factors present in pre-TAVR and post-TAVR sera would affect myofibroblast activation in vitro. Myofibroblast activation was quantified as the percentage of cells containing α-smooth muscle actin (α-SMA) stress fibers in an immunofluorescence image. Aortic VICs seeded on tissue culture polystyrene (TCPS) treated with serum from patients before and after TAVR showed no significant differences in myofibroblast activation, although serum from patients A, B, C, D, and E showed trends toward decreased activa-

Vic transcriptome reveals pathways regulating myofibroblast phenotype in TAVR serum

Next, we sought to identify critical signaling pathways involved in serum-mediated myofibroblast activation. Using next-generation
RNA sequencing techniques to characterize the transcriptome of VICs treated with pre-TAVR and post-TAVR sera, we hypothesized that key signaling pathways would emerge as potential regulators of serum-mediated myofibroblast activation. After comparing the counts per million read values for all samples (n = 8 pre-TAVR patients and n = 8 post-TAVR patients), 1193 genes were differentially expressed in VICs treated with pre-TAVR serum relative to post-TAVR serum (FDR-adjusted P-value cutoff of 0.05; table S5 in data file S1). A mean-difference (MD) plot depicted the 619 up-regulated and 574 down-regulated genes in pre-TAVR serum, as well as the genes with expression changes greater than 1.0 or less than −1.0 log-twofold change relative to post-TAVR samples (Fig. 2A). From the differentially regulated gene list, we curated genes specific to cytoskeletal organization (nine up and two down), ECM remodeling (seven up and six down), and fibrocalcification (five up and three down) processes (Fig. 2B), which revealed a myofibroblast phenotypic shift from pre-TAVR to post-TAVR (Fig. 2C).

Next, we cataloged the most relevant pathways up- and down-regulated in response to patient serum samples using the Kyoto...
Encyclopedia of Genes and Genomes (KEGG) database. For up-regulated genes, the mitogen-activated protein kinase (MAPK) pathway, Hippo pathway, and pathways associated with focal adhesion were enriched and top ranked according to the gene ratio of up-regulated genes to the total number of genes in the pathway (table S6 in data file S1 and Fig. 2D).

Next, we identified upstream regulators of myofibroblast activation present in pre-TAVR serum that act on the MAPK signaling pathway. We generated interaction networks with our list of differentially regulated genes in pre-TAVR serum using the Ingenuity Pathway Analysis (IPA) and added the 15 candidate factors regulating myofibroblast activation in pre-TAVR serum (Fig. 1H) to the top-ranked curated interaction network. Expanding the network by one interaction to include our 15 candidate factors as nodes showed 7 of 15 factors connected to the network generated using IPA, which serve as upstream regulators of p38 MAPK (Fig. 2F).

Individual factors in pre-TAVR serum activate VICs on hydrogel valve–ECM mimics

To validate candidate factors as inducers of myofibroblast activation, we used physiologically relevant hydrogel microenvironments that allow culture of quiescent VIC fibroblasts. We evaluated the role of
IFN-γ, BMP-6, and CXCL9, three of the seven candidate factors identified as upstream regulators of MAPK signaling from our IPA analysis (Fig. 2F). We observed increased myofibroblast activation as a function of IFN-γ, BMP-6, and CXCL9 concentrations in VICs seeded on soft hydrogels (Fig. S4).

Next, we evaluated the ability of post-TAVR serum to deactivate VICs initially activated with BMP-6, CXCL9, or IFN-γ and assessed variability in deactivation as a function of patient sera. During a 5-day study, VICs were seeded on soft hydrogels, treated with 100 ng/ml of IFN-γ, BMP-6, or CXCL9, and then treated with control or post-TAVR serum from four patients. Patient-specific fold changes in post-TAVR deactivation were observed (Fig. 3A). VICs activated to a myofibroblast state when treated with BMP-6, despite removing BMP-6 in exchange for control medium, whereas post-TAVR serum deactivated VICs (Fig. 3B). BMP-6–activated VICs deactivated in the presence of post-TAVR serum (four of four patient sera tested) (Fig. 3C), with patient-specific differences in the extent of deactivation (Fig. 3D). Similarly, CXCL9 activated VICs to a myofibroblast state, whereas post-TAVR serum deactivated cells (Fig. 3E). CXCL9–activated VICs returned to a quiescent state in the presence of post-TAVR serum from all four patient sera tested (Fig. 3F), with patient-specific differences in deactivation (Fig. 3G). In contrast, IFN-γ did not maintain VIC activation upon removal of the cue (Fig. 3H). Using post-TAVR serum treatments, only one of four patients’ sera reduced VIC activation after IFN-γ treatment (Fig. 3I), although we

**Fig. 3.** Pre-TAVR serum factors (BMP-6, CXCL9, and IFN-γ) mediate myofibroblast activation. (A) Schematic of valvular activation experiments with BMP-6, CXCL9, and IFN-γ (created with BioRender). Representative images of porcine VICs treated initially with (B) BMP-6, (C) CXCL9, or (D) IFN-γ for 2 days (left column) and then treated with either control media or post-TAVR serum (right column). Stains: green, α-SMA; magenta, cytoplasm; blue, nuclei. Scale bars, 100 μm. Percentage of activated VICs initially activated with (E) BMP-6, (F) CXCL9, or (H) IFN-γ and deactivated with post-TAVR serum from four patients. Patient-specific fold changes in post-TAVR deactivation in VICs initially activated with (D) BMP-6, (G) CXCL9, or (J) IFN-γ. Groups with different letters indicate statistical significance (n = 9 measurements per group, means ± SD shown, one-way ANOVA with Tukey posttests, P < 0.05).
did observe patient-specific differences in deactivation as previously observed with BMP-6 and CXCL9 (Fig. 3J). Together, our data suggest that post-TAVR serum contains factors that deactivate myofibroblasts initially treated with candidate factors identified in pre-TAVR serum.

**Pre-TAVR serum regulates myofibroblast activation via MAPK signaling**

The convergence of our proteomic and transcriptomic results on MAPK signaling as a candidate pathway mediating myofibroblast activation in pre-TAVR serum suggested that we validate the potential role of p38 MAPK in mediating downstream α-SMA stress fiber formation. We first confirmed VICs had reduced α-SMA stress fiber formation, even in the highly activating TCPS microenvironment, in the presence of SB203580, a small-molecule inhibitor of p38 MAPK activity (fig. S5). Using SB203580 to inhibit p38 MAPK activity in VICs seeded on soft hydrogels, we observed that p38 MAPK–inhibited VICs had decreased myofibroblast activation in response to pre-TAVR serum from four patients (selected because of serum availability) (Fig. 4A). For three of four serum samples tested, we observed decreased α-SMA stress fiber formation in VICs treated with 20 μM SB203580 relative to vehicle controls (Fig. 4B). We also observed decreased myofibroblast activation using SB203580 in the presence of individual cytokines (Fig. 4C). Specifically, treatment with 20 μM SB203580 reduced myofibroblast activation in the presence of BMP-6 and CXCL9 relative to vehicle controls (Fig. 4D).

**Post-TAVR serum reverses valvular myofibroblast activation on soft and stiff hydrogels**

Next, we tested the ability of post-TAVR serum to reverse the activated myofibroblast phenotype using our controlled in vitro hydrogel model. VICs are rampantly activated toward a myofibroblast state on TCPS, and we did not observe any deactivation of TCPS-cultured VICs in the presence of post-TAVR serum (fig. S6). VICs activated to a myofibroblast state using pre-TAVR serum for 48 hours were then treated with either pre-TAVR or post-TAVR serum from the same patient (Fig. 5A). In the soft hydrogel microenvironments, we observed deactivation, or reversal of the pre-TAVR–mediated activation of VICs, by exposure to post-TAVR patient serum (Fig. 5B). For six of eight patients, VICs remained highly activated in pre-TAVR serum, but the activation was reversed in the presence of post-TAVR serum (Fig. 5C). We also observed differences in the fold change deactivation of myofibroblasts between patients (Fig. 5D). There was no significant correlation between the fold change deactivation values for each patient according to aortic valve area values measured using echocardiography (Fig. 5E).

To determine whether VIC activation was context specific, we tested whether myofibroblasts would revert to a fibroblast (quiescent) phenotype in response to serum cues if the microenvironment was stiffer, similar to that of diseased, fibrotic valve tissue. First, we confirmed the percentage of activated myofibroblasts was greater on stiff (55.5 ± 10.5%) relative to soft (37.0 ± 11.0%) hydrogels (fig. S7). Post-TAVR serum deactivated myofibroblasts on stiff hydrogels (Fig. 5F). VICs treated with pre-TAVR serum remained highly activated on stiff hydrogels, but the myofibroblast population decreased in the presence of post-TAVR serum from six of eight patients (Fig. 5G). Patient-specific differences in post-TAVR serum–mediated deactivation were also apparent on stiff hydrogels (Fig. 5H). We observed a significant negative correlation between fold change deactivation values and aortic valve area measured by echocardiography, suggesting a link between in vitro myofibroblast deactivation on stiff hydrogels and valve area, where decreased valve area serves as an indicator of AVS disease severity (Fig. 5I).
Post-TAVR serum reverses cardiac myofibroblast activation on soft and stiff hydrogels

Given clinical data suggesting fibrotic left ventricular tissue remodels after TAVR, we investigated how post-TAVR serum factors deactivate cardiac myofibroblasts. LV ARVFs were seeded on soft or stiff hydrogels and treated with pre-TAVR and post-TAVR sera, as described for VICs (Fig. 5A). Fibrotic cardiac tissue is considerably stiffer than fibrotic valvular tissue (22, 23); therefore, we altered our stiff hydrogel formulation to generate 278-kPa hydrogels (fig. S2). We confirmed ARVFs are mechanosensitive, because ARVFs maintained low activation on soft hydrogels in both FBS (24.0 ± 6.6%) and healthy human serum (28.6 ± 21.4%) but increased activation on stiff hydrogels (FBS, 61.7 ± 8.1%; healthy human serum, 60.1 ± 16.8%) (fig. S8).

Pre-TAVR serum activated ARVFs seeded on soft hydrogels to differentiate into myofibroblasts, and a subsequent post-TAVR serum treatment deactivated the cells (Fig. 6A). For five of eight patients, ARVFs activated in pre-TAVR serum and deactivated when treated with post-TAVR serum (Fig. 6B). Patient-specific deactivation fold changes were observed (Fig. 6C), which correlated with deactivation fold changes observed in VICs (fig. S9). Cardiac myofibroblasts showed high activation in pre-TAVR serum on stiff hydrogels, and activation was significantly reduced in post-TAVR serum (Fig. 6D). For seven of eight patients, ARVFs were activated by pre-TAVR serum and deactivated upon treatment with post-TAVR serum (Fig. 6E), showing patient-specific deactivation (Fig. 6F).

Fold change deactivation values of ARVFs treated with individual patient sera on soft hydrogels did not correlate with Society of Thoracic Surgery (STS) risk scores of patient mortality after TAVR (Fig. 6G); however, STS scores correlated with patient-specific serum deactivation values on stiff hydrogels (Fig. 6H). Similarly, ARVF deactivation data on soft hydrogels did not correlate with left ventricular...
Fig. 6. Post-TAVR serum deactivates cardiac myofibroblasts activated with pre-TAVR serum on soft and stiff hydrogels. (A) Representative images and (B) percentage of activated ARVFs on soft hydrogels treated initially with pre-TAVR serum and subsequently with either pre-TAVR or post-TAVR serum. (C) Fold change of ARVF deactivation on soft hydrogels in post-TAVR serum (\( \Delta_{\text{post}} \)) normalized to the mean activation in pre-TAVR serum from the same patient (\( \Delta_{\text{pre}} \)). (D) Representative images and (E) percentage of activated ARVFs on stiff hydrogels treated initially with pre-TAVR serum and subsequently with either pre-TAVR or post-TAVR serum. (F) Fold change of ARVF deactivation on stiff hydrogels in post-TAVR serum (\( \Delta_{\text{post}} \)) normalized to the mean activation in pre-TAVR serum from the same patient (\( \Delta_{\text{pre}} \)). (G and H) Scatter plots of fold change in ARVF deactivation on (G) soft and (H) stiff hydrogels versus patient STS scores. (I and J) Scatter plots of patient fold change in ARVF deactivation on soft hydrogels versus (I) LVIDs and (J) LVIDd measurements. (K and L) Scatter plots of fold change in ARVF deactivation on stiff hydrogels versus patient (K) LVIDs and (L) LVIDd measurements. Stained images: green, -SMA; yellow, cytoplasm; blue, nuclei. Scale bars, 100 \( \mu \)m. For all bar graphs, \( n = 9 \) measurements per group, means \pm SD shown, and significance tested with one-way ANOVA for all data and indicated as * \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \), **** \( P < 0.0001 \), or groups with different letters indicate statistical significance (\( P < 0.05 \)).

Validating inflammatory factors mediating myofibroblast deactivation using stiff hydrogels

Given the complex milieu of factors present in post-TAVR serum that override mechanical signals from the matrix environment, we next sought to validate key serum proteins as mediators of the observed myofibroblast deactivation. On the basis of our SOMAscan internal diameter measurements in both systole (LVIDs; Fig. 6I) and diastole (LVIDd; Fig. 6J), whereas stiff hydrogel ARVF deactivation data negatively correlated with LVIDs (Fig. 6K) and LVIDd (Fig. 6L) measurements. Thus, ARVFs that were less reversible in vitro corresponded to more severely diseased patients with reduced LV diameters due to wall thickening.
results, we selected the inflammatory cytokines IL-1β and TNF-α, which were both more abundant in post-TAVR serum relative to pre-TAVR serum. We hypothesized that TNF-α and IL-1β would deactivate myofibroblasts on stiff hydrogels, and subsequently observed decreases in myofibroblast activation as a function of cytokine concentration (Fig. S10). VICs cultured on stiff hydrogels treated with pre-TAVR serum remained activated when subsequently treated with control media, whereas activated cells subsequently treated with IL-1β and TNF-α (10 ng/ml) deactivated, with reduced α-SMA stress fiber formation (Fig. 7, A and B). For three of four serum samples tested, IL-1β and TNF-α deactivated pre-TAVR–activated VICs (Fig. 7C). Patient-specific differences were observed in the deactivation fold changes (Fig. 7, D and E).

Next, we queried the role of inflammatory cytokines released from M1 proinflammatory macrophages in deactivating VICs. THP-1 monocytes were differentiated into M1 macrophages and used to generate conditioned media for VIC culture. As hypothesized, conditioned medium from M1 macrophages deactivated VICs seeded on stiff hydrogels in a concentration-dependent manner (Fig. 7, F and G). Enzyme-linked immunosorbent assay (ELISA) confirmed that conditioned medium from M1 macrophages contained increased TNF-α (562.7 ± 68.5 pg/ml) and IL-1β (207.1 ± 12.3 pg/ml) relative to control medium (Fig. 7H), further suggesting these M1 macrophage factors are involved in deactivating myofibroblasts.

**Sex-specific differences in serum-mediated activation and deactivation**

Recognizing that male and female patients experience different outcomes in fibrotic tissue remodeling after TAVR (24, 25), we reanalyzed our VIC activation and deactivation data, looking for differences in responses to serum from male and female patients. We observed that five of eight pre-TAVR samples and six of eight post-TAVR samples from male patients clustered together and three of four post-TAVR serum samples from female patients clustered together (fig. S11). Pooling the quantified myofibroblast activation results according to the sex of the patient demonstrated that 26.5 ± 9.8% of VICs treated with post-TAVR serum from male patients were activated to myofibroblasts, lower than 37.4 ± 8.4% of VICs treated with post-TAVR serum from female patients (Fig. 8A). The fold change in VIC activation was reduced in male serum relative to female serum (Fig. 8B).

Upon reanalyzing our pre-TAVR versus post-TAVR proteomic results and separating by sex (n = 8 male patients and n = 4 female patients), we observed a total of 39 proteins with abundance changes in female serum, whereas we observed 347 proteins to have altered abundances in male serum, with 88 differentially regulated proteins in common between sexes (Fig. 8C). IL-1β and TNF-α were more abundant in male post-TAVR serum relative to pre-TAVR serum; BMP-6 was more abundant in male pre-TAVR serum relative to post-TAVR; and CXCL9 and IFN-γ were more abundant in both male and female pre-TAVR serum relative to post-TAVR serum (table S8 in data file S1). Reanalyzing our transcriptomics data (n = 4 male patients and n = 4 female patients) revealed a total of 23 genes in VICs were differentially regulated when treated with female serum, whereas 452 genes were differentially regulated when treated with male serum, with 35 differentially regulated genes in common between male and female serum-treated VICs (Fig. 8D and table S9 in data file S1).

We also observed sex-specific differences in our deactivation experiments on hydrogel substrates. On soft hydrogels, VICs treated with male pre-TAVR serum for the entire experiment had higher activation relative to female pre-TAVR serum treatments, and VICs deactivated with post-TAVR serum showed less deactivation in male serum relative to female serum (Fig. 8, E and F). Similar trends were observed in ARVFs, where male and female post-TAVR serum deactivated myofibroblasts on soft substrates, with less deactivation in male serum relative to female serum (Fig. 8, G and H). Because we demonstrated that deactivation fold changes on stiff hydrogels correlated with patient data, we next analyzed sex differences in deactivation on stiff hydrogels. VICs treated with serum from male and female patients activated in pre-TAVR and deactivated in post-TAVR similarly (Fig. 8I), with no change in fold change deactivation (Fig. 8J). However, ARVF-treated male post-TAVR serum showed greater deactivation relative to ARVF-treated female serum (Fig. 8K), with a reduction in fold change activation levels (Fig. 8L).

**DISCUSSION**

Here, we quantified the differences in circulating factor composition in patient sera after a TAVR procedure, identifying factors that promote valvular and cardiac myofibroblast deactivation. We suggest inflammatory macrophages arriving to valve implants partially contribute to altering secreted factors in the blood and promote an antifibrotic phenotype to assist left ventricular reverse remodeling (24). Prior studies of transcatheter aortic valves suggest proinflammatory immune cells accumulate along the artificial valve leaflet, indicating immune cells arrive and adhere to the implant (26). Although other contributors, including activation of the renin-angiotensin system (27) and reduction in sympathetic activity after TAVR (28), can lead to systemic alterations in serum factors, our data suggest that the systemic inflammation response to the TAVR implant is involved in altering the composition of patient serum factors, at least when measured at an acute 30-day time point. Our SOMAscan proteomic (29) and GO analysis strategy shows enrichment of dozens of proteins associated with the inflammation response after TAVR, particularly proteins traditionally secreted by inflammatory macrophages, including TNF-α and IL-1β. TNF-α and IL-1β secreted from proinflammatory macrophages were shown to deactivate myofibroblasts on stiff hydrogels, supporting the premise that inflammatory proteins partially regulate myofibroblast deactivation after a TAVR procedure.

The role of TNF-α and IL-1β in mediating myofibroblast phenotypes has been controversial (30, 31). TNF-α has been previously shown to reduce α-SMA expression in myofibroblasts (32), reduce collagen production via nuclear factor κB signaling (33), inhibit TGF-β myofibroblast signaling (34), and have increased abundance in serum after TAVR and SAVR (14, 35). Likewise, IL-1β has been shown to mitigate TGF-β1–mediated cardiac myofibroblast activation (36). In contrast, other studies suggest TNF-α secretion from inflammatory macrophages promotes osteogenic differentiation of VICs (37–40). In addition, IL-1 receptor antagonist knockout mice spontaneously develop AVS, which implicates IL-1β in promoting calcification (41). Considering our in vitro results, we posit that the effects of TNF-α and IL-1β after TAVR are tissue specific. In valvular tissue, VICs likely adopt an antifibrotic and procalcific phenotype in response to TNF-α and IL-1β during AVS progression. After a TAVR procedure, elevated TNF-α and IL-1β secreted from proinflammatory macrophages would contribute to modifying the valve tissue microenvironment, potentially influencing bioprosthetic
and native valve restenosis and other structural deteriorations around the annulus in the long term (14, 42, 43). In cardiac tissue, TNF-α and IL-1β likely participate in deactivating myofibroblasts in left ventricular tissue, because previous work has shown these factors decrease collagen production and increase MMP activity (44). Open questions remain regarding the effects of TNF-α and IL-1β (and potentially other post-TAVR factors) in mediating osteogenic VIC differentiation and subsequent valve restenosis given their procalcific effects, even though these factors may provide antifibrotic benefits to diseased cardiac tissue. Collectively, evidence supports the notion that serum factors (such as TNF-α, IL-1β, and other post-TAVR factors) may play a critical role in myofibroblast deactivation after TAVR, which could further affect valvular and cardiac fibrosis and potentially be used as markers to monitor a patient’s beneficial response to TAVR.

The use of soft hydrogel culture platforms enabled the unambiguous assessment of inflammatory factors on the fibroblast-to-myofibroblast...
transition by decoupling mechanically induced myofibroblast activation. Because TCPS automatically activates fibroblasts to myofibroblasts, hydrogel culture platforms are an essential tool for studying valvular and cardiac fibroblast phenotypes and myofibroblast activation in vitro (18, 21, 45–48). Our results on soft hydrogels implicate serum factors in patients with AVS as drivers of myofibroblast activation in valvular and cardiac tissue relative to healthy serum controls, suggesting serum factors exacerbate tissue fibrosis during AVS.
Merging high-throughput datasets (49–51) yielded candidate proteins in the pre-TAVR serum milieu that may serve to promote myofibroblast activation via the p38 MAPK pathway. Signaling via p38 MAPK has been implicated in driving myofibroblast activation during fibrosis progression in different tissues (52–55). Proteins upstream of the MAPK pathway according to our IPA analysis, including IFN-γ, BMP-6, and CXCL9, were validated as candidate factors mediating myofibroblast activation, thus implicating these factors in partially contributing to AVS progression (56, 57). Future work comparing concentrations of IFN-γ, BMP-6, and CXCL9 in patients with AVS relative to healthy patients may further implicate these factors as biomarkers and contributors to AVS progression. Together, our soft hydrogel system serves as a critical tool for maintaining fibroblast quiescence to probe the roles of serum factors and signaling pathways that may drive myofibroblast activation and subsequent AVS progression.

Post-TAVR serum also deactivates valvular and cardiac myofibroblasts on stiff, fibrotic-like microenvironments, and the fold change in deactivation correlates with measures of patient disease severity (smaller aortic valve area, higher STS score, and lower LVIDs/LVIDd measurements). We suggest that our engineered hydrogels can serve as in vitro models to support precision medicine and serve as precision biomaterials that enable patient-specific evaluation of disease (58). As an example, previous clinical work suggests LV reverse remodeling is predictive of improved survival outcomes after TAVR, where patients lacking LV reverse remodeling were observed to die within the first year after TAVR (13). Given that improvements in LV remodeling correlate with TAVR outcomes and serum factors after TAVR mediate myofibroblast deactivation in fibrotic microenvironments, we posit that earlier TAVR procedures may prove beneficial for patients with AVS to prevent further fibrosis progression and promote tissue remodeling. Because valve and cardiac fibrosis are difficult to treat and no known drugs exist to reverse or slow disease progression (59), we also envision an opportunity to develop in vitro models that more accurately reflect in vivo disease context to identify new pathways for drugs to target fibrosis. Although our results reveal the potential impact of this strategy, future work is needed to fully evaluate our in vitro correlations with patient data, especially studies that include larger sample sizes, tracking patient sera with time, and/or using human-derived fibroblast populations. Given prior reports suggesting cardiac tissue remodeling occurs over months after aortic valve replacement (24), evaluating the longitudinal effects of post-TAVR serum factors in patients (at least 6 months) may further reveal the potential role of serum factors in mediating long-term fibrotic tissue remodeling. However, the reported results support the role of engineered biomaterials and in vitro models to advance the understanding of disease context in vivo; this complementary integration of in vitro engineered biomaterials and in vitro models to support precision medicine and serve as precision biomaterials will become increasingly important. Collectively, we suggest engineered biomaterial in vitro culture systems coupled with biochemical cues from sera provide a more clinically relevant in vitro platform to generate in vitro models of heart disease to provide a bridge to better understand disease progression and resolution after TAVR in vivo. Of course, the complex interplay between extracellular biochemical and mechanical cues regulating valvular and cardiac fibrosis will certainly require further investigation. Because the field seeks to identify drugs and treatments to reduce detrimental, persistent myofibroblast activation in fibrotic valve and cardiac tissues. This was confirmed by in vitro experiments that enabled a systematic evaluation of the effects of patient-specific serum factors on VICs and ARVF and their myofibroblast activation and deactivation. Specifically, hydrogel culture systems that recapitulate soft tissue, as well as fibrotic microenvironments, were used to generate in vitro models of heart disease to provide a bridge to better understand disease progression and resolution after TAVR in vivo. Of course, the complex interplay between extracellular biochemical and mechanical cues regulating valvular and cardiac fibrosis will certainly require further investigation. Because the field seeks to identify drugs and treatments to reduce detrimental, persistent myofibroblast activation in fibrotic valve and cardiac tissues, model systems that allow researchers to elucidate the effects of differential and synergistic microenvironmental factors will become increasingly important. Collectively, we suggest engineered biomaterial in vitro culture systems coupled with biochemical cues from sera provide a more clinically relevant in vitro model for understanding disease context in vivo, which may lead to identifying patient-specific mechanisms of AVS progression and pathways to customized treatments and earlier interventions.

MATERIALS AND METHODS

Study design

We hypothesized serum factors before a TAVR procedure would activate valvular and cardiac fibroblasts to myofibroblasts, whereas...
Table S2. SOMAscan proteomic results.

Table S3. GO analysis for pre-TAVR serum factors.

Table S4. GO analysis for post-TAVR serum factors.

Table S5. Transcriptional results for VICs treated with pre-TAVR versus post-TAVR serum.

Table S6. KEGG enrichment for up-regulated genes in pre-TAVR samples.

Table S7. KEGG enrichment for down-regulated genes in pre-TAVR samples.

Table S8. Sex-specific analysis of proteomic data.

Table S9. Sex-specific analysis of transcriptional data.

Data file S2. Individual subject-level raw values for all experiments (Excel file).

Reference (73)

REFERENCES AND NOTES

1. R. M. Weiss, J. D. Miller, D. D. Heidat, Fibrocalcific aortic valve disease: Opportunity to understand disease mechanisms using mouse models. *Circ. Res.* 113, 209–222 (2013).

2. J. D. Carroll, TAVR prognosis, aging, and the second TAVR tsunami: Insights from France. *J. Am. Coll. Cardiol.* 68, 1648–1650 (2016).

3. R. L. J. Osnabrugge, D. Mylotte, S. J. Head, N. M. Van Mieghem, V. T. Nkomo, C. M. LeReun, A. J. J. C. Bogers, N. Piazza, A. P. Kappetein, Aortic stenosis in the elderly: Disease prevalence and number of candidates for transcatheter aortic valve replacement: A meta-analysis and modeling study. *J. Am. Coll. Cardiol.* 62, 1002–1012 (2013).

4. T. P. Vahl, S. K. Kodali, M. B. Leon, Transcatheter aortic valve replacement 2016: A modern-day “through the looking-glass” adventure. *J. Am. Coll. Cardiol.* 67, 1427–1487 (2016).

5. C. M. Otto, B. Prendergast, Aortic-valve stenosis—From patients at risk to severe valve obstruction. *N. Engl. J. Med.* 371, 744–756 (2014).

6. M. B. Leon, C. R. Smith, M. Mack, D. C. Miller, J. W. Moses, L. G. Svensson, E. M. Tuzcu, J. G. Webb, G. P. Fontana, R. R. Makkar, D. L. Brown, P. C. Block, R. A. Guyton, A. D. Pichard, J. E. Bavaria, H. C. Herrmann, P. S. Douglas, J. L. Petersen, J. J. Akin, W. N. Anderson, D. Wang, S. Pocock; PARTNER Trial Investigators, Transcatheter aortic valve implantation for aortic stenosis in patients who cannot undergo surgery. *N. Engl. J. Med.* 363, 1597–1607 (2010).

7. G. Marquis-Gravel, B. Redfors, M. B. Leon, P. Généreux, Medical treatment of aortic stenosis. *Circulation* 134, 1766–1784 (2016).

8. P. Généreux, S. J. Head, D. A. Wood, S. K. Kodali, M. R. Williams, J.-M. Paradis, M. Spaziano, A. P. Kappetein, J. G. Webb, A. Cribier, M. B. Leon, Transcatheter aortic valve implantation 10-year anniversary: Review of current evidence and clinical implications. *Eur. Heart J.* 33, 2388–2398 (2012).

9. C. R. Smith, M. B. Leon, M. J. Mack, D. C. Miller, J. W. Moses, L. G. Svensson, E. M. Tuzcu, J. G. Webb, G. P. Fontana, R. R. Makkar, M. T. Temple, D. Wehby, S. Kapadia, V. Bablaalarios, V. H. Thourani, P. Corso, A. D. Pichard, J. E. Bavaria, H. C. Herrmann, J. J. Akin, W. N. Anderson, D. Wang, S. J. Pocock; PARTNER Trial Investigators, Transcatheter aortic-implantation for aortic stenosis in patients who cannot undergo surgery. *N. Engl. J. Med.* 363, 2187–2198 (2011).

10. M. J. Reardon, D. H. Adams, N. S. Kleiman, S. J. Yakubov, J. S. Coselli, G. M. Deeb, T. G. Gleason, J. S. Lee, J. B. Herrmiller Jr., S. Chetcuti, J. Heiser, W. Merhi, G. L. Zorn Ill, P. Tadros, N. Robinson, G. Petrosian, G. C. Hughes, J. K. Harrison, B. Maini, M. Muntz, J. V. Conte, J. R. Resar, V. Aharonov, T. Pfeffer, J. K. Oh, H. Qiao, J. J. Pocap, 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. *J. Am. Coll. Cardiol.* 66, 113–121 (2015).

11. H. Wang, L. A. Leinwand, K. S. Anseth, Cardiac valve cells and their microenvironment—Insights from in vitro studies. *Nat. Rev. Cardiol.* 11, 715–727 (2014).

12. A. Orkan, S. Kapadia, M. Tuzcu, T. H. Marwick, Assessment of left ventricular function in aortic stenosis. *Nat. Rev. Cardiol.* 8, 494–501 (2011).

13. K. Sato, A. Kumar, B. M. Jones, S. L. Mck, A. Krishnaswamy, R. A. Grimm, M. Y. Desai, B. P. Griffin, L. L. Rodriguez, S. R. Kapadia, N. A. Obuchowski, Z. B. Popovic, Reversibility of cardiac function predicts outcome after transcatheter aortic valve replacement in patients with severe aortic stenosis. *J. Am. Heart Assoc.* 6, e005798 (2017).

14. J. Sušenkov, P. Toulouk, V. Kocca, F. Bednář, H. Línková, R. Petr, M. Laboš, P. Widimský, Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement. *J. Cardiovasc. Med.* 69, 483–488 (2017).

15. G. Erdös, C. Lippuner, I. Kocsis, M. Schiff, M. Stucki, T. Carrel, S. Windecker, B. Eberle, F. Stueber, M. Beucher, Technical approach determines inflammatory response after surgical and transcatheter aortic valve replacement. *PLoS ONE* 10, e0143089 (2015).

16. K. M. Mabry, L. R. Lawrence, K. S. Anseth, Dynamic stiffening of polyethylene glycol-based hydrogels to direct valvular interstitial cell phenotype in a three-dimensional environment. *Biomaterials* 49, 47–56 (2015).

17. B. D. Fairbanks, M. P. Schwartz, A. E. Halevi, C. R. Nusseln, C. N. Bowman, K. S. Anseth, A versatile synthetic extracellular matrix mimic via thiol-sorbentborne photopolymerization. *Adv. Mater.* 21, S505–S501 (2009).
18. A. M. Klooxin, J. A. Benton, K. S. Anserth, In situ elasticity modulation with dynamic substrates to direct cell phenotype. Biomaterials 31, 1–8 (2010).
19. H. Wang, S. M. Haeger, A. M. Klooxin, L. A. Leinwand, K. S. Anserth, Redirecting valvular myofibroblasts into dormant fibroblasts through light-mediated reduction in substrate modulus. PLOS ONE 7, e93966 (2012).
20. H. Wang, M. W. Tibbritt, S. J. Langer, L. A. Leinwand, K. S. Anserth, Hydrogels preserve native phenotypes of valvular fibroblasts through an elasticity-regulated P3K/AKT pathway. Proc. Natl. Acad. Sci. U.S.A. 110, 19336–19341 (2013).
21. S. T. Gould, N. J. Darling, K. S. Anserth, Small peptide functionalized thiol–ene hydrogels as culture substrates for understanding valvular interstitial cell activation and de novo tissue deposition. Acta Biomater. 8, 3201–3209 (2012).
22. M. F. Berry, A. J. Engler, Y. J. Woo, T. J. Prolli, L. T. Bish, V. Jayasankar, J. K. Morine, T. J. Gardner, D. E. Discher, H. L. Sweeney, Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am. J. Physiol. Heart Circ. Physiol. 290, H2196–H2203 (2006).
23. W. Hiesinger, M. J. Brukman, R. C. McCormick, J. R. Fitzpatrick III, J. R. Frederick, E. C. Yang, J. R. Muenzer, N. A. Marotta, M. F. Berry, P. Alturi, Y. J. Woo, Myocardial tissue elastic properties determined by atomic force microscopy following SDF-1α angiogenic therapy for acute myocardial infarction. J. Thorac. Cardiovasc. Surg. 143, 962–966 (2012).
24. L. E. Dobson, T. A. Fairbairn, T. A. Musa, A. C. Mundie, P. P. Swoboda, D. P. Ripley, A. M. Blackburn, K. M. Ziada, J. C. Gurley, L. E. Dobson, T. A. Fairbairn, T. A. Musa, A. Uddin, C. A. Mundie, P. P. Swoboda, D. P. Ripley, A. M. Blackburn, K. M. Ziada, J. C. Gurley, Redirecting valvular myofibroblasts into dormant fibroblasts through light-mediated reduction in substrate stiffness: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J. Am. Coll. Cardiol. 63, 1522–1528 (2014).
25. K. Yahagi, S. Tori, E. Ladich, R. Kutsy, M. E. Romero, H. Mori, F. D. Koldoge, J. J. Popma, R. Virmani, A. V. Finn, Pathology of self-expanding transcatheter aortic valve: Findings from the CoreValve US pivotal trials. Catheter. Cardiovasc. Interv. 91, 947–958 (2015).
26. T. Inohara, P. Manandhar, A. S. Kosinski, R. A. Matsouka, S. Koshaka, R. J. Meintz, N. J. Weissman, A. J. Kurtine, M. B. Leon, Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J. Am. Coll. Cardiol. 63, 2221–2234 (2015).
27. N. Dumontel, A. Vaccaro, F. Despaz, M. Labrunere, B. Marchex, E. Lambert, M. Esler, D. Carrie, J. M. Senard, M. Galinier, A. Pathak, Transcatheter aortic valve implantation reduces sympathetic activity and normalizes arterial spontaneous baroreflex in patients with aortic stenosis. JACC Cardiovasc. Interv. 6, 1195–1202 (2013).
28. L. Gold, D. Ayers, J. Bertino, C. Bock, E. N. Brody, J. Carter, A. B. Dalby, B. E. Eaton, J. P. Greenwood, Sex-related differences in left ventricular remodeling in severe aortic stenosis and reverse remodeling after aortic valve replacement: A cardiovascular magnetic resonance study. Am. Heart J. 175, 101–111 (2016).
29. M. Williams, S. K. Kodali, R. T. Hahn, K. H. Humphries, V. T. Nkomo, D. J. Cohen, P. S. Douglas, M. Mack, T. C. McAndrew, L. Svensson, V. H. Thourani, E. M. Tuzcu, N. J. Weissman, A. J. Kurtine, M. B. Leon, Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J. Am. Coll. Cardiol. 63, 2221–2234 (2015).
30. B. A. Aguado, D. A. Chapkin, A. L. Vientos, X. Liu, K. S. Anserth, A reversible and repeatable thiol–ene bioconjugation for dynamic patterning of signaling proteins in hydrogels. ACS Cent. Sci. 4, 909–918 (2018).
31. B. A. Aguado, J. J. Wu, S. M. Azarin, D. Nanavati, S. R. Rao, G. G. Bushell, C. B. Medicherla, L. D. Shea, Secretome identification of immune cell phenotypes mediating metastatic cell homing. Sci. Rep. 5, 17566 (2015).
32. F. Schlott, A. Halu, S. Goto, M. C. Blaser, S. C. Body, H. Higashi, D. M. DeLaughter, D. H. Hutschen, P. Vyas, T. Pham, A. Rogers, A. Sharma, C. E. Seidman, J. L. Liscoal, J. G. Seidman, M. Akawa, S. A. Singh, E. Akawa, Spatiotemporal multi-omics mapping generates a molecular atlas of the aortic valve and reveals networks driving valve disease. Circulation 138, 377–393 (2018).
33. B. A. Aguado, R. M. Hartford, G. G. Bushell, J. T. Decker, S. M. Azarin, D. Nanavati, M. J. Schipma, S. S. Rao, R. S. Oakes, Y. Zhang, J. S. Jeruss, L. D. Shea, Biomaterial scaffolds as pre-metastatic niche mimics systemically alter the primary tumor and tumor microenvironment. Adv. Healthc. Mater. 7, e1700938 (2018).
34. L. Li, D. Fan, C. Wang, J.-Y. Wang, X.-B. Cui, D. W., Y. D., Z. Hou, L.-L. Wu, Angiotensin II increases peroxisome proliferator-activated receptor gamma/hypoxia inducible factor-1α expression via p38 MAPK-ERK and PI3K/Akt pathways in cardiac fibroblasts. Circ. Res. 91, 80–89 (2011).
35. M. Sato, D. Shegogue, E. A. Gore, E. A. Smith, P. J. Mcdermott, M. Trojanowska, Role of p38 MAPK in transforming growth factor β stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J. Invest. Dermatol. 118, 704–711 (2002).
36. T. G. Voloshenyuk, E. S. Landesman, E. Khorotova, A. D. Hart, J. D. Gardner, Induction of cardiac fibroblast lysyl oxidase by TGF-β1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine 55, 90–97 (2011).
37. J. D. Molkentin, D. Bugg, N. Ghearing, L. E. Dom, P. Kim, M. A. Sargent, J. Gunaye, K. Otsu, J. Davis, Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation 136, 549–561 (2017).
38. E. Nagy, Y. Lei, E. Martinez-Martinez, S. C. Body, F. Schlott, M. Creager, A. Amsmann, K. Khabbaz, P. Libby, G. K. Hansson, E. Akawa, Interferon-γ released by activated CD8+ T lymphocytes impairs the calcium resorption potential of osteoclasts in calcified human aortic valves. Am. J. Pathol. 187, 1413–1425 (2017).
39. E. Nagy, D. C. Anderson, K. Caidahl, M. J. Eriksson, S. Eriksson, A. Franco-Cereceda, G. K. Hansson, M. Bäck, Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123, 1136–1137 (2011).
58. C. M. McCoy, D. Q. Nicholas, K. S. Masters, Sex-related differences in gene expression by porcine aortic valve interstitial cells. *PLOS ONE* **7**, e39980 (2012).
59. J. S. Borer, A. Sharma, Drug therapy for heart valve diseases.
60. B. A. Aguado, J. C. Grim, A. M. Rosales, J. J. Watson-Capps, K. S. Anseth, Engineering precision biomaterials for personalized medicine. *Sci. Transl. Med.* **10**, eaam8645 (2018).
61. A. M. Porras, C. M. McCoy, K. S. Masters, Calcific aortic valve disease: A battle of the sexes. *Circ. Res.* **120**, 604–606 (2017).
62. Y. Srinath, M. Enriquez-Sarano, H. V. Schaff, G. Casガンラclang-Verzosa, J. D. Miller, Pathophysiology of aortic valve stenosis: Is it both fibrocaldic and sex specific? *Physiology (Bethesda)* **32**, 182–196 (2017).
63. R. Zusterzeel, N. K. Mishra, H. Beydoun, J. Laschinger, C. Wu, L. M. Dong, J.-A. Lin, D. Marinac-Dabic, D. G. Strauss, D. A. Caños, Sex-specific outcomes after transcatheter aortic valve replacement: FDA patient-level meta-analysis of premarket clinical trials. *J. Womens Health (Larchmt)* **27**, 808–814 (2018).
64. S. Kodali, M. R. Williams, D. Doshi, R. T. Hahn, K. H. Humphries, V. T. Nikom, D. J. Cohen, P. S. Douglas, M. Mack, K. Xu, L. Svendsen, V. H. Thourani, E. M. Tuzcu, N. J. Weissman, M. Leon, A. J. Kirtane, Sex-specific differences at presentation and outcomes among patients undergoing transcatheter aortic valve replacement: A cohort study. *Ann. Intern. Med.* **164**, 377–384 (2016).
65. J. J. Thaden, V. T. Nikomo, R. M. Suri, J. J. Maesleszewski, M. A. Clavel, S. V. Pisanu, J. F. Malouf, T. A. Foley, J. K. Oh, J. D. Miller, W. D. Edwards, M. Enriquez-Sarano, Sex-related differences in calcific aortic stenosis: Correlating clinical and echocardiographic characteristics and computed tomography aortic valve calcium score to excised aortic valve weight. *Eur. Heart J.* **37**, 693–699 (2015).
66. B. Villari, S. E. Campbell, J. Schneider, G. Vassali, M. Chiariello, O. M. Hess, Sex-dependent differences in left ventricular function and structure in chronic pressure overload. *Eur. Heart J.* **16**, 1410–1419 (1995).
67. L. E. Dobson, T. A. Fairbairn, S. Plein, J. P. Greenwood, Sex differences in aortic stenosis and outcome following surgical and transcatheter aortic valve replacement. *J. Womens Health (Larchmt)* **24**, 986–995 (2015).
68. D. Nigo, S. Sinha, D. Shen, M. K. Keyes, X. Shi, M. D. Benson, J. F. O’Sullivan, H. Keshishian, L. A. Farrell, M. A. Fiffer, R. S. Vasam, M. S. Sabatine, M. G. Larson, S. A. Carr, T. J. Wang, R. E. Gerszten, Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. *Circulation* **134**, 270–285 (2016).
69. Y. Liao, G. K. Smyth, W. Shi, featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
70. T. Metsalu, J. Vilo, ClustVis: A web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. *Nucleic Acids Res.* **43**, W566–W570 (2015).
71. M. Pertea, D. Kim, G. M. Pertea, J. T. Leek, S. L. Salzberg, Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. *N. Protoc.* **11**, 1650–1667 (2016).
72. G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, clusterProfiler: An R package for comparing biological themes among gene clusters. *OMICS* **16**, 284–287 (2012).
73. M. Genin, F. Clement, A. Fattaccioli, M. Raes, C. Michiels, M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. *BMC Cancer* **15**, 577 (2015).

**Acknowledgments:** We thank O. Cho and A. Doan (Genomics and Microarray Core, University of Colorado Anschutz Medical School) for performing the SOMAscan DNA aptamer array. We thank A. Scott and K. Hammond (BioFrontiers Institute Next-Generation Sequencing Core Facility, University of Colorado Boulder), who performed the RNA library construction and Illumina sequencing. We thank E. Gill (University of Colorado Anschutz School of Medicine) for summarizing the patient data. We also thank the TAVR patients for providing the serum needed to conduct the studies. **Funding:** B.A.A. acknowledges funding from the NIH (F32 HL137256 and K99 HL148542) and the Burroughs Welcome Fund Postdoctoral Enrollment Program. J.C.G. acknowledges funding from the NIH (T32 HL007822). C.J.W. acknowledges funding from the NSF (IGERT 1144807), the U.S. Department of Education GAANN Fellowship, and the NIH (F31 HL142223). T.L.C. acknowledges support from the American Heart Association (17PRE33661129). C.C.S. acknowledges support from the NIH (HL139968 and HL119533). L.A.L. acknowledges funding from the NIH (R01 GM029090). T.A.M. acknowledges funding from the NIH (HL116848, HL147558, DK 119594, and HL127240) and the American Heart Association (16SFRN31400013). K.S.A. acknowledges funding from the NIH (R01 DE016523, R01 HL132353, and R21 AR067469) and the NSF (DMR 1408955). **Author contributions:** B.A.A. performed and analyzed in vitro hydrogel experiments using VICs and ARVFs, analyzed proteomic and transcriptomic data, identified patient data correlations, and wrote the manuscript. K.B.S. performed TAVR procedures, collected serum samples, and collected patient data. J.C.G. performed and analyzed inflammatory macrophage conditioned media experiments. C.J.W. analyzed transcriptomic data. A.C.C. performed ontological analysis of proteomic data. T.L.C. performed ARVF isolations and assisted with immunostaining. A.-C.T. analyzed proteomic data. C.C.S. collected and provided healthy human serum samples. L.A.L. provided access to rats and assisted in the experimental design and interpretation of ARVF experiments. M.R.G.T. provided access to TAVR patient sera and obtained IRB approvals. K.S.A. and T.A.M. led the study, provided expertise, and wrote and edited the manuscript.

**Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data associated with this study are available in the paper or the Supplementary Materials. Raw sequencing files and processed data files are available in the NCBI GEO database with accession number GSE133529. All data and materials used in the analysis will be made available to any researcher for purposes of reproducing or extending the analyses performed.

Submitted 18 October 2018
Resubmitted 25 March 2019
Accepted 17 July 2019
Published 11 September 2019
10.1126/scitranslmed.aav3233

**Citation:** B. A. Aguado, K. B. Schuetzke, J. C. Grim, C. J. Walker, A. C. Cox, T. L. Ceccato, A.-C. Tan, C. C. Sucharow, L. A. Leinward, M. R. G. Taylor, T. A. McKinsey, K. S. Anseth, Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation. *Sci. Transl. Med.* **11**, eaav3233 (2019).